217 related articles for article (PubMed ID: 15231869)
1. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
[TBL] [Abstract][Full Text] [Related]
2. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Lazo JS; Nemoto K; Pestell KE; Cooley K; Southwick EC; Mitchell DA; Furey W; Gussio R; Zaharevitz DW; Joo B; Wipf P
Mol Pharmacol; 2002 Apr; 61(4):720-8. PubMed ID: 11901209
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913
[TBL] [Abstract][Full Text] [Related]
5. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Johnston PA; Foster CA; Tierno MB; Shun TY; Shinde SN; Paquette WD; Brummond KM; Wipf P; Lazo JS
Assay Drug Dev Technol; 2009 Jun; 7(3):250-65. PubMed ID: 19530895
[TBL] [Abstract][Full Text] [Related]
6. A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.
Aoyagi Y; Masuko N; Ohkubo S; Kitade M; Nagai K; Okazaki S; Wierzba K; Terada T; Sugimoto Y; Yamada Y
Cancer Sci; 2005 Sep; 96(9):614-9. PubMed ID: 16128747
[TBL] [Abstract][Full Text] [Related]
7. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
Lazo JS; Aslan DC; Southwick EC; Cooley KA; Ducruet AP; Joo B; Vogt A; Wipf P
J Med Chem; 2001 Nov; 44(24):4042-9. PubMed ID: 11708908
[TBL] [Abstract][Full Text] [Related]
8. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
[TBL] [Abstract][Full Text] [Related]
9. EK-6136 (3-methyl-4-(O-methyl-oximino)-1-phenylpyrazolin-5-one): a novel Cdc25B inhibitor with antiproliferative activity.
Kim KR; Kwon JL; Kim JS; No Z; Kim HR; Cheon HG
Eur J Pharmacol; 2005 Dec; 528(1-3):37-42. PubMed ID: 16324698
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition.
Sodeoka M; Sampe R; Kojima S; Baba Y; Usui T; Ueda K; Osada H
J Med Chem; 2001 Sep; 44(20):3216-22. PubMed ID: 11563920
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Schepetkin IA; Karpenko AS; Khlebnikov AI; Shibinska MO; Levandovskiy IA; Kirpotina LN; Danilenko NV; Quinn MT
Eur J Med Chem; 2019 Dec; 183():111719. PubMed ID: 31563013
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
Lavecchia A; Di Giovanni C; Pesapane A; Montuori N; Ragno P; Martucci NM; Masullo M; De Vendittis E; Novellino E
J Med Chem; 2012 May; 55(9):4142-58. PubMed ID: 22524450
[TBL] [Abstract][Full Text] [Related]
13. Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.
Kolb S; Mondésert O; Goddard ML; Jullien D; Villoutreix BO; Ducommun B; Garbay C; Braud E
ChemMedChem; 2009 Apr; 4(4):633-48. PubMed ID: 19212959
[TBL] [Abstract][Full Text] [Related]
14. Redox regulation of Cdc25B by cell-active quinolinediones.
Brisson M; Nguyen T; Wipf P; Joo B; Day BW; Skoko JS; Schreiber EM; Foster C; Bansal P; Lazo JS
Mol Pharmacol; 2005 Dec; 68(6):1810-20. PubMed ID: 16155209
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Cossy J; Belotti D; Brisson M; Skoko JJ; Wipf P; Lazo JS
Bioorg Med Chem; 2006 Sep; 14(18):6283-7. PubMed ID: 16782352
[TBL] [Abstract][Full Text] [Related]
16. Modeling of Cdc25B dual specifity protein phosphatase inhibitors: docking of ligands and enzymatic inhibition mechanism.
Lavecchia A; Cosconati S; Limongelli V; Novellino E
ChemMedChem; 2006 May; 1(5):540-50. PubMed ID: 16892390
[TBL] [Abstract][Full Text] [Related]
17. Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone.
Brisson M; Foster C; Wipf P; Joo B; Tomko RJ; Nguyen T; Lazo JS
Mol Pharmacol; 2007 Jan; 71(1):184-92. PubMed ID: 17018577
[TBL] [Abstract][Full Text] [Related]
18. Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.
Braud E; Goddard ML; Kolb S; Brun MP; Mondésert O; Quaranta M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2008 Oct; 16(19):9040-9. PubMed ID: 18789703
[TBL] [Abstract][Full Text] [Related]
19. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.
Pu L; Amoscato AA; Bier ME; Lazo JS
J Biol Chem; 2002 Dec; 277(49):46877-85. PubMed ID: 12356752
[TBL] [Abstract][Full Text] [Related]
20. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
Tamura K; Southwick EC; Kerns J; Rosi K; Carr BI; Wilcox C; Lazo JS
Cancer Res; 2000 Mar; 60(5):1317-25. PubMed ID: 10728693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
